SCHEMBL6789421

SCHEMBL6789421

CN(C)c1cccc(C(N)=O)c1.Nc1cc(N2C(=O)c3ccccc3C2=O)c(F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 1/20 0.39
CYP3A4 P08684 1/20 0.39
NFKB1 P19838 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
RORC P51449 1/20 0.37
MAPT P10636 2/20 0.36
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36
MCL1 Q07820 1/20 0.36
PARP1 P09874 1/20 0.36
PARP15 Q460N3 1/20 0.36
PARP10 Q53GL7 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GRM1 Q13255 3/20 0.35
GRM4 Q14833 2/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7729097 0.80 CYP3A4 (0.56) CYP3A4NFKB1PMP22GRM1GRM4
SCHEMBL6678591 0.77 MAPT (0.50) SMN1; SMN2KDM4ELMNAMAPTNPC1
SCHEMBL6789418 0.71 GRM4 (0.46) GRM1GRM4GRM7CYP2C9HDAC3
SCHEMBL4252143 0.71 PARP1 (0.57) FYNSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL893991 0.71 PARP1 (0.57) FYNSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL6683298 0.70 CYP3A4 (0.60) CYP3A4NFKB1PMP22GRM1GRM4
SCHEMBL6681443 0.70 MAPT (0.57) CYP3A4SMN1; SMN2KDM4ELMNAMAPT
Hydrochloric Acid SCHEMBL3862436 0.69 PARP1 (0.55) FYNSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL7731694 0.69 ESR1 (0.46) CYP3A4NFKB1PMP22KDM4EGRM1
SCHEMBL5388823 0.68 ESR1 (0.49) CYP3A4NFKB1PMP22GRM1GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716847-B2 ANTIALLERGENS, ANTIINFLAMMATORY ASTRAZENECA AB (SE) 2004-04-06 US disclosed
US-6593333-B1 Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various ASTRAZENECA AB (SE) 2003-07-15 US disclosed
EP-1117653-B1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-02-05 EP disclosed
EP-1117653-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2001-07-25 EP disclosed
WO-2000020402-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2000-04-13 WO disclosed